Top Medical News
Pearl Toh, 39 minutes ago
Indication and demand for genetic testing have increased in recent years, with tests becoming more readily available and affordable, says a leading oncologist at the ESMO Asia 2017, highlighting that appreciation of ethical, social, and legal implications of testing and proper test interpretation are important for optimal patient management.
Roshini Claire Anthony, 21 hours ago

A modified (lower-dose) of XELIRI with or without bevacizumab may be an alternative second-line chemotherapy treatment for patients with metastatic colorectal cancer (CRC), according to results of the noninferiority phase III AXEPT* trial. 

Yesterday
It appears that a proinflammatory potential of the diet does not have a significant relationship with the risk of developing colorectal tumours (CRTs) in patients with Lynch syndrome (LS), according to a study.
2 days ago
Profiling of primary pheochromocytomas and paragangliomas with matrix-assisted laser desorption-ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) can identify diseases with metastatic potential based on their different asparagine-linked glycan (N-glycan) structures, according to a study conducted at Helsinki University Hospital and Glykos Finland Ltd.
3 days ago
Resveratrol, piceatannol and analogues demonstrate a high potency both as inhibitors of androgen synthesis and androgen receptor activation, according to a study, suggesting the potential of such compounds in the chemoprevention of prostate cancer.
5 days ago
In patients with renal cell carcinoma, mean platelet volume is a highly significant risk factor for recurrence and cancer-specific death, a recent study has found. This parameter enhances the accuracy of the Leibovich prognosis score to better predict long-term outcomes in localized renal cell carcinoma cases following curative surgical resection.
6 days ago
Severity of malignancy, preoperative serum albumin concentration, intraoperative blood loss and duration of operation, among other factors, predict postoperative pneumonia (POP) development following major oral cancer (OC) surgery, a recent study has found.
Special Reports
20 Sep 2017
Sustained stable disease with regorafenib in heavily pretreated metastatic colon cancer
Dr. Alexander Drilon, 19 Jul 2017
With the dramatic evolution of sequencing technology and emergence of effective targeted therapies, using a comprehensive molecular approach to guide treatment decisions is becoming more accessible and applicable in the clinic. At the recent Foundation Medicine meeting in Hong Kong, Dr Alexander Drilon, clinical director of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center (MSKCC), New York, US, discussed the current landscape and potential benefits of comprehensive molecular profiling in non-small cell lung cancer (NSCLC).
Prof. Ignatius Ou Sai Hong, Dr. James Suh, Dr. Wong Seng Weng, Dr. Amit Verma, 14 May 2017
As targeted cancer therapy options are increasing, it is becoming more important to choose the most appropriate treatment for patients with cancer. At a Roche-sponsored symposium held during the 2nd ESMO Asia Congress in Singapore, four experts discussed the potential of comprehensive genomic profiling (CGP) for personalizing cancer care and helping healthcare professionals to make the best treatment decisions for individual patients.
Dr. Ross Soo, Prof. James Chih-Hsin Yang, Prof. Tony Mok, Prof. Fred Hirsch, 28 Mar 2017
Classification and treatment of non-small cell lung cancer (NSCLC) has greatly evolved in recent years. A better understanding of this complex malignancy has led to a shift from histologic diagnosis to more accurate subclassification using molecular screening which, in turn, led to the transition from empiric treatment to molecular target therapy. At the European Society for Medical Oncology (ESMO) Asia 2016 Congress in Singapore, Dr Ross Soo from the National University Cancer Institute, Singapore, Professor James Chih-Hsin Yang from the National Taiwan University Hospital, Taiwan, Professor Tony Mok from The Chinese University of Hong Kong, Hong Kong, and Professor Fred Hirsch from the University of Colorado Cancer Center, Colorado, US presented therapeutic biomarker-driven strategies for improving outcomes in patients with NSCLC. The discussion focused on the role and impact of molecular target therapy using epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) biomarkers and T-cell-based immunotherapy in coming up with algorithms to guide clinicians in selecting the best treatment regimen for each patient.
14 Mar 2017
Over 20 leading surgical and medical oncologists from Singapore attended a dinner meeting on the Neoadjuvant treatment of early breast cancer (eBC). Co-chaired by Dr Veronique Tan (National Cancer Centre, Singapore) and Dr Elaine Lim (National Cancer Centre, Singapore), the meeting served as a platform to discuss the role of neoadjuvant therapy in eBC management. Guest speakers, Professor J. Michael Dixon OBE (Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom) and Dr Rebecca Dent (National Cancer Centre, Singapore) shared their perspectives on the benefits of neoadjuvant therapy in different BC subtypes.
31 Jan 2017
At the launch of Caris Molecular Intelligence® in Malaysia, Dr Andrew Dean, Head of Oncology at the St John of God Subianco Hospital, Perth, shared with the audience on molecular profiling and its benefits, with a focus on the Caris Molecular Intelligence® service.
16 Dec 2016
KEYTRUDA – Pembrolizumab 100 mg/4 mL soln for inj – Merck Sharp & Dohme
Conference Reports
Pearl Toh, 22 Nov 2017
Indication and demand for genetic testing have increased in recent years, with tests becoming more readily available and affordable, says a leading oncologist at the ESMO Asia 2017, highlighting that appreciation of ethical, social, and legal implications of testing and proper test interpretation are important for optimal patient management.
Roshini Claire Anthony, 21 Nov 2017

A modified (lower-dose) of XELIRI with or without bevacizumab may be an alternative second-line chemotherapy treatment for patients with metastatic colorectal cancer (CRC), according to results of the noninferiority phase III AXEPT* trial. 

Dr. Joseph Delano Fule Robles, 08 Nov 2017

Aggressive dose de-escalation of radiotherapy provides similar efficacy and superior safety profile in patients with human papilloma virus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC), according to a recent study presented at the 2017 Annual Meeting of the American Society for Radiation Oncology (ASTRO). 

Jackey Suen, 08 Nov 2017

Hypofractionated radiotherapy (HFRT) is equally effective and safe compared with conventional fractionated RT (CFRT) in Chinese breast cancer patients who have undergone mastectomy, according to a phase III study presented at the American Society for Radiation Oncology (ASTRO) 2017 Annual Meeting. [ASTRO 2017, abstract 5]

Jackey Suen, 01 Nov 2017

Use of consolidative stereotactic ablative radiotherapy (SAbR) prior to maintenance chemotherapy improves progression-free survival (PFS) by more than 6 months in patients with non-small-cell lung cancer (NSCLC) who have limited metastases, a recent phase II study has shown. [ASTRO 2017, abstract LBA3; JAMA Oncol 2017, doi: 10.1001/jamaoncol.2017.3501]

Dr. Joseph Delano Fule Robles, 31 Oct 2017

Combination therapy with the CTLA-4 blocker, ipilimumab, and stereotactic ablative radiation therapy (SABR) is effective in cancers with metastatic lung and liver lesions, according to results presented at the 2017 Annual Meeting of the American Society for Radiation Oncology (ASTRO).

Rachel Soon, 30 Oct 2017

Integrating robust smoking cessation programs with organized low-dose CT (LDCT) lung cancer screening may decrease mortality rates while being relatively cost-effective, according to a modelling study.

Product Highlights
CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD